An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

BACKGROUND: The radiopharmaceutical (131)I-meta-iodobenzylguanidine ((131)I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from (131)I-MIBG is likely to be obtained by its combination with chemotherapy. We previously reported enhanced antitumour efficacy of (...

Descripción completa

Detalles Bibliográficos
Autores principales: Nile, Donna L., Rae, Colin, Hyndman, Iain J., Gaze, Mark N., Mairs, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982014/
https://www.ncbi.nlm.nih.gov/pubmed/27515310
http://dx.doi.org/10.1186/s12885-016-2656-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982014/
https://www.ncbi.nlm.nih.gov/pubmed/27515310
http://dx.doi.org/10.1186/s12885-016-2656-8

Ejemplares similares